EMA says ingestible sensor can be used as trial biomarker
Data can be transmitted from the device via wearable sensors to computer devices for processing and analysis
The European Medicines Agency (EMA) has said that an ingestible sensor system developed by US-based pharmaceutical firm Proteus Digital Health can be used as a biomarker to measure patient adherence to medication in clinical trials.
EMA’s Committee for Medicinal Products for Human Use (CHMP) has said the technology is a 'qualified method' for achieving this goal. Its assessment noted how the Proteus system can be 'co-formulated with active pharmaceutical compounds into drug/device combinations, integrating measuring of medication adherence into oral pharmacotherapy'.
Data can be transmitted from the device via wearable sensors to computer devices for processing and analysis, explained a committee note.